Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Acute Toxicity: dermal

Currently viewing:

Administrative data

Endpoint:
acute toxicity: dermal
Type of information:
experimental study
Adequacy of study:
key study
Study period:
Aug to Sep 1995
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
comparable to guideline study with acceptable restrictions
Cross-reference
Reason / purpose for cross-reference:
reference to same study

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1996
Report date:
1996

Materials and methods

Test guidelineopen allclose all
Qualifier:
according to guideline
Guideline:
other: Amendment to Annex VI of the Oirective 67/548 EEC in the version of EEC Directive 93/21 EEC and "Gefahrstoffverordnung, Stand Oct. 94".
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 402 (Acute Dermal Toxicity)
Version / remarks:
1981
Deviations:
yes
Remarks:
3 instead of 5 animals/sex used
GLP compliance:
yes
Remarks:
- but a QA check was not performed
Test type:
standard acute method
Limit test:
yes

Test material

Constituent 1
Chemical structure
Reference substance name:
Hydroxyprogesterone acetate
EC Number:
206-119-6
EC Name:
Hydroxyprogesterone acetate
Cas Number:
302-23-8
Molecular formula:
C23H32O4
IUPAC Name:
3,20-dioxopregn-4-en-17-yl acetate

Test animals

Species:
rat
Strain:
other: HAN: WIST (SPF)
Sex:
male/female
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Schering AG
- Age at study initiation: not specified
- Weight at study initiation: males: 112-120 g; females: 101-107 g
- Fasting period before study: ca. 16.5-19 h
- Housing: single housing
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 7 days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 23-24°C
- Humidity (%): 58-62%
- Air changes (per hr): not specified
- Photoperiod (hrs dark / hrs light): 12/12

IN-LIFE DATES: From: To: males: 30. Aug - 12. Sep 1995; females 6. - 19. Sep 1995

Administration / exposure

Type of coverage:
semiocclusive
Vehicle:
other: 0.9% (w/v) NaCl-solution
Details on dermal exposure:


TEST MATERIAL
- Amount(s) applied: males 224-240 mg; females 202 - 214 mg
- For solids, paste formed: yes

VEHICLE
- Amount(s) applied: males 0.4 ml; females 0.3 ml
Duration of exposure:
24 hours
Doses:
2000 mg/kg bw
No. of animals per sex per dose:
3
Control animals:
no
Details on study design:
- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: day 1, 7 and 14
- Necropsy of survivors performed: yes
Statistics:
not applicable

Results and discussion

Effect levels
Key result
Sex:
male/female
Dose descriptor:
LD50
Effect level:
> 2 000 mg/kg bw
Based on:
test mat.
Mortality:
No animal died during the study.
Clinical signs:
other: The test item was tolerated without compound-related findings.
Gross pathology:
Autopsy revealed no compound-related findings.

Applicant's summary and conclusion

Conclusions:
A single dermal administration of the test substance to male and female rats at the limit-dose 2000 mg/kg was tolerated without mortalities, compound-related clinical findings, effects on body weight gain and gross pathological findings. The dermal LD50 of the test substance is therefore > 2000 mg/kg body weight.
Executive summary:

In an acute dermal toxicity study similar to OECD TG 402 performed as a combined study on acute toxicity and on local tolerance HAN: WIST rats (3/sex) (3/sex) were dermally exposed to hydroxyprogesterone acetate in physiological saline for 24 hours at a limit dose of 2000 mg/kg bw under semiocclusive conditions.  Animals then were observed for 14 days.


The administration of the test substance was tolerated without mortalities, compound-related clinical findings, effects on body weight gain and gross pathological findings.


The dermal LD50 of the test substance is therefore > 2000 mg/kg body weight.